Atea Pharmaceuticals, Inc. financial data

Symbol
AVIR on Nasdaq
Location
Boston, MA
Fiscal year end
31 December
Latest financial report
10-K - Q4 2025 - 05 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1440% % -20%
Debt-to-equity 9% % 20%
Return On Equity -46% % -29%
Return On Assets -43% % -27%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 79,672,083 shares -6.8%
Common Stock, Shares, Outstanding 78,126,796 shares -7.5%
Entity Public Float $262,600,000 USD 3.8%
Common Stock, Value, Issued $78,000 USD -7.1%
Weighted Average Number of Shares Outstanding, Basic 81,495,352 shares -3.3%
Weighted Average Number of Shares Outstanding, Diluted 81,495,352 shares -3.3%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $148,024,000 USD 2.7%
General and Administrative Expense $32,863,000 USD -33%
Operating Income (Loss) $180,887,000 USD 6.3%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $164,511,000 USD 1.8%
Income Tax Expense (Benefit) $6,162,000 USD -766%
Net Income (Loss) Attributable to Parent $158,349,000 USD 6%
Earnings Per Share, Basic -1.94 USD/shares 3%
Earnings Per Share, Diluted -1.94 USD/shares 3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $95,713,000 USD 48%
Cash, Cash Equivalents, and Short-term Investments $301,830,000 USD -34%
Assets, Current $310,991,000 USD -33%
Property, Plant and Equipment, Net $457,000 USD -48%
Operating Lease, Right-of-Use Asset $634,000 USD -49%
Other Assets, Noncurrent $3,136,000 USD 1492%
Assets $315,218,000 USD -32%
Accounts Payable, Current $12,945,000 USD 190%
Employee-related Liabilities, Current $6,438,000 USD 9%
Liabilities, Current $39,784,000 USD 114%
Accrued Income Taxes, Noncurrent $0 USD -100%
Operating Lease, Liability, Noncurrent $0 USD -100%
Liabilities $39,784,000 USD 54%
Accumulated Other Comprehensive Income (Loss), Net of Tax $174,000 USD -25%
Retained Earnings (Accumulated Deficit) $522,569,000 USD -43%
Stockholders' Equity Attributable to Parent $275,434,000 USD -37%
Liabilities and Equity $315,218,000 USD -32%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $30,563,000 USD 23%
Net Cash Provided by (Used in) Financing Activities $347,000 USD -331%
Net Cash Provided by (Used in) Investing Activities $85,608,000 USD 51%
Common Stock, Shares Authorized 300,000,000 shares 0%
Common Stock, Shares, Issued 78,126,796 shares -7.5%
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $54,698,000 USD 220%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $95,713,000 USD 48%
Deferred Tax Assets, Valuation Allowance $162,328,000 USD 38%
Deferred Tax Assets, Gross $162,328,000 USD 38%
Operating Lease, Liability $843,000 USD -49%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $158,408,000 USD 5.9%
Lessee, Operating Lease, Liability, to be Paid $855,000 USD -49%
Property, Plant and Equipment, Gross $1,978,000 USD 0%
Operating Lease, Liability, Current $843,000 USD 5.4%
Lessee, Operating Lease, Liability, to be Paid, Year Two $855,000 USD 2%
Lessee, Operating Lease, Liability, to be Paid, Year One $855,000 USD 2%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $12,000 USD -76%
Deferred Tax Assets, Operating Loss Carryforwards $56,408,000 USD 189%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $0 USD -100%
Additional Paid in Capital $797,751,000 USD -0.62%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance $0 USD
Share-based Payment Arrangement, Expense $20,720,000 USD -60%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%